HSV Reactivation

Status: draft compiled 2026-04-20.

Herpes simplex virus (HSV-1 and HSV-2) reactivation after laser hair removal in a dermatome harbouring latent virus is an under-appreciated complication that is fully preventable with appropriate prophylaxis. The mechanism is the same as for reactivation after any mechanical or thermal stimulus to the affected nerve territory: the virus resides in sensory ganglia between outbreaks, and local tissue injury upregulates neural signalling that can precipitate reactivation and subsequent vesicular eruption. Because laser hair removal on face (perioral HSV-1) and genital region (HSV-2, HSV-1 genital) are both common treatment areas, and because the affected populations include a substantial fraction of patients with latent HSV, prophylaxis should be a routine discussion for any patient with a documented history.

Evidence base

The evidence base for antiviral prophylaxis in laser skin procedures comes primarily from laser skin resurfacing rather than from laser hair removal, but the mechanism is the same and the extrapolation is widely accepted. Beeson & Rachel 2002, Dermatol Surg, PMID 11966791 reported 100% HSV prevention with valacyclovir 500 mg BID starting one day before laser resurfacing in a randomised trial. Subsequent laser-hair-removal case reports document reactivation events in patients without prophylaxis: HSV-2 perianal reactivation after alexandrite laser hair removal in an HIV+ patient, PMID 33448730. No RCT of prophylaxis specifically in laser hair removal exists through April 2026; the evidence base is extrapolated from resurfacing plus case-report-driven practice. Confidence: C2.

Prophylaxis regimen

Standard practice for a patient with documented HSV history and planned laser in the affected dermatome:

• Valacyclovir 500 mg orally twice daily × 10-14 days, starting the day before the session and continuing for about a week after.
• Alternative: acyclovir 400 mg orally TID × 10-14 days starting the day before. Valacyclovir is preferred because of better bioavailability and simpler BID dosing.
• For patients planning multiple sessions: restart prophylaxis one day before each session.

Confidence: C2.

Who needs prophylaxis

• Any patient with documented recurrent HSV-1 (orolabial herpes) undergoing laser in the perioral region (upper lip, chin, jawline, full-face).
• Any patient with documented recurrent HSV-2 or genital HSV-1 undergoing laser on genital, perianal, or pubic skin.
• Any patient with a history of a single HSV outbreak in the intended treatment area — recurrence rate in these patients is lower than in frequently-recurrent cases but still non-zero.
• Immunocompromised patients (HIV, iatrogenic immunosuppression) with any HSV history should have broader prophylaxis consideration.

Patients without documented HSV history do not need prophylactic antivirals; empirical prophylaxis for all laser hair removal patients is not standard. Confidence: C3.

Management of a new or breakthrough eruption

A patient developing a vesicular eruption in the treated area within 1-14 days of a session should be evaluated for HSV reactivation; HSV PCR or viral culture can confirm. Immediate treatment with valacyclovir 1000 mg BID × 5-10 days (therapeutic dose, higher than prophylactic) accelerates resolution and reduces post-lesion complications. The session should not be considered a "failure" — the hair-removal effect is independent of the HSV reactivation — but future sessions in the same area require prophylaxis from the day before.

Breakthrough HSV on prophylaxis is uncommon but occurs; doubling the prophylactic dose (valacyclovir 1000 mg BID) for subsequent sessions is reasonable. Confidence: C3.

When HSV is undocumented

Many patients have never had HSV seropositive testing and may carry latent virus without ever having had a symptomatic outbreak. Empirical prophylaxis for all patients is not standard because of the cost and small side-effect profile of valacyclovir, but clinicians should specifically ask about history of cold sores, genital outbreaks, or family members with HSV before perioral or genital laser sessions. A patient who is uncertain but reports possible subclinical symptoms should consider prophylaxis anyway; the downside is minimal. Confidence: C3.

What this is not

HSV reactivation is not a contraindication to laser hair removal. It is a preventable complication that requires prophylaxis in the at-risk subset. A patient with extensive HSV history can safely complete a full facial or genital laser course on prophylaxis.

HSV reactivation is also not a reason to choose electrolysis over laser; the same mechanical-trauma-triggers-HSV mechanism applies to electrolysis in patients with latent virus, and the same prophylactic antiviral regimen is appropriate for electrolysis in the affected dermatome. Choice of modality should be made on the independent efficacy and cost considerations; HSV status is a separate and manageable axis. Confidence: C3.